Financial Information

Latest Financial Results


Revenue for the first quarter ended March 31, 2021 was $0.4 million.


As of March 31, 2021, Adaptimmune had cash and cash equivalents of $32.4 million and Total Liquidity of $317.9 million.

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

For complete information regarding our financials, see our periodic filings

Balance Sheet

Includes Current Assets, Liabilities and Stockholder's Equity

View Balance Sheet

Income Statement

Includes Total Net Sales, Cost & Expenses and Earnings per share

View Income Statement

Cash Flow

Includes Net Income, Adjustments, and Cash flows from investing & financing activities

View Cash Flow